secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUTRO BIOPHARMA, INC. (STRO)
CIK:        0001382101
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001193125-25-269833
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sutro Biopharma Q3 revenue $9.7M, cash $167.6M; IND cleared for STRO-004
------------------------------------------------------------------------

- FDA cleared IND for STRO-004 (Tissue Factor ADC); first patient dosing expected before year-end.
- Cash, cash equivalents and marketable securities were $167.6M at Sept. 30, 2025, down from $388.3M a year earlier.
- Revenue was $9.7M (vs $8.5M Q3 2024), primarily from Astellas collaboration.
- R&D and G&A expenses totaled $48.6M, down from $76.4M in Q3 2024.
- Organizational restructuring expected to extend cash runway into at least mid-2027; restructuring costs estimated at $4.1M–$4.3M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1382101/000119312525269833/0001193125-25-269833-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1382101/000119312525269833/stro-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-269833

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer